Legal Representation
Attorney
Susan Weller
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 6, 2025 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Mar 26, 2025 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Feb 25, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Feb 25, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Feb 19, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jan 30, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 30, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Jan 30, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Jan 30, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Jan 30, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Jan 29, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 29, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jan 29, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jan 28, 2025 | DOCK | D | ASSIGNED TO EXAMINER |
| Jan 15, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Nov 21, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Nov 21, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Nov 21, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Nov 21, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Nov 21, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jul 15, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of pain disorders, folding disorders, and secretory diarrhea; pharmaceutical preparations, namely, a drug for the purpose of targeting ion channels and membrane transporters; pharmaceutical preparations, namely, a drug for the purpose of targeting ion channels and membrane transporters for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical preparations for the treatment of pain through activation of specific K+ channels in the peripheral nervous system; pharmaceutical preparations for the treatment of folding disorders via the detection of surface-expression of membrane proteins; pharmaceutical preparations for the purpose of limiting dehydration for patients suffering from secretory diarrhea; pharmaceutical preparations for the treatment of physiological diseases
Class 042
Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research for the purpose of treating pain disorders, folding disorders, and secretory diarrhea; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine
Additional Information
Translation
The English translation of the word "TOPO" in the mark is "mole".
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"